Planning Ahead: Maintenance Therapy in Endometrial Cancer

Statement of Need

The Food and Drug Administration (FDA) recently approved immune checkpoint inhibitors (ICIs) for patients with advanced or recurrent endometrial cancer (EC) who did not respond to first-line treatment with chemotherapy. This led to several new trials of emerging therapies, including studies to determine if progression-free survival (PFS) could be improved with the addition of chemotherapy.

With the advent of ICI therapy and emerging ICI combination therapies, clinicians need to have knowledge of where and how maintenance therapy may play a role in improving PFS in EC. During this podcast, international gynecologic cancer experts Drs. Richard Penson and Nicoletta Colombo discuss the most recent data from these EC trials, focusing on how it has changed recommended practice patterns and how it should be incorporated into the care of patients with EC.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Assess the role of maintenance therapy in the treatment of EC

Financial Support

Supported by a joint educational grant from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Target Audience

Primary Audiences: Medical oncologists, gynecologic oncologists, physician assistants (PAs), nurses, nurse practitioners (NPs), and pharmacists working in oncology settings
Secondary Audiences: Gynecologists and primary care physicians (PCPs)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-24-011-H01-P).

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Penson reports the following financial relationships:

Advisory Board: Aadi Bioscience; AstraZeneca; GSK; ImmunoGen, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Novacure; Roche; Sutro Biopharma, Inc.; and Vascular Biogenics

Consultant: Serves on DSMBs for AstraZeneca; EQRx; and Roche

Research Support: Intuitional research funding (as PI) for Array BioPharma Inc.; AstraZeneca; Eisai Inc.; Genentech, Inc.; and Vascular Biogenics

Other financial or material support: Royalties: BMJ Publishing Group Ltd; Elsevier; UpToDate, Inc.; Wolters Kluwer Health and Wiley-Blackwell. Payment for educational events: Research to Practice; ExpertConnect; and ReachMD

Dr. Colombo reports the following financial relationships:

Advisory Board: AstraZeneca; Clovis Oncology; Eisai; GSK; Immunogen; Mersana; MSD/Merck; Novocure; Nuvation Bio; Oncxema; Pieris; and Roche

Research Support: AstraZeneca and GSK

Speakers Bureau: AstraZeneca; Clovis; MSD/Merk; GSK; and Eisai
Investigator/Researcher: AstraZeneca; GSK; and Roche

The following individuals have no financial relationships to disclose:

Jeffrey Helfand, DO (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Thomas Mitchell (Planning Committee)
David Modrak, PhD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

PD-100-020124-90

Planning Ahead: Maintenance Therapy in Endometrial Cancer

Faculty

Statement of Need

Learning Objectives

Financial Support

Target Audience